IN006 / Shenzhen Shenxin Biotechnology - LARVOL DELTA

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults (clinicaltrials.gov) - P1 | N=200 | Not yet recruiting | Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd | Trial completion date: Oct 2026 ➔ Apr 2028 | Trial primary completion date: Apr 2026 ➔ Apr 2028

Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IL4

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above (clinicaltrials.gov) - P1 | N=240 | Active, not recruiting | Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • IL4

A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older (clinicaltrials.gov) - P2 | N=500 | Active, not recruiting | Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older (clinicaltrials.gov) - P2 | N=500 | Recruiting | Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd

New P2 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A randomized, double-blind, Phase 1, single- and multiple-dose placebo-controlled study of the safety and pharmacokinetics of IN-006, an inhaled antibody treatment for COVID-19 in healthy volunteers. (PubMed, EBioMedicine) - P1 | "IN-006 was well-tolerated and achieved concentrations in the respiratory tract orders of magnitude above the IC50 range typical of antiviral mAbs. These data support further development of nebulized delivery of antiviral mAbs for respiratory infectious disease."

Clinical • Journal • P1 data • PK/PD data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults (clinicaltrials.gov) - P1 | N=200 | Not yet recruiting | Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd | Initiation date: Aug 2024 ➔ Aug 2025

Trial initiation date • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above (clinicaltrials.gov) - P1 | N=240 | Recruiting | Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above (clinicaltrials.gov) - P1 | N=240 | Not yet recruiting | Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd

New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adults (clinicaltrials.gov) - P1 | N=200 | Not yet recruiting | Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd

New P1 trial • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections